Yen Wei-Chen, Yang Ming-Hsin, Weng Tzu-Hsuan, Chung Chi-Hsiang, Tsao Chang-Huei, Tsao Chih-Wei, Meng En, Wu Sheng-Tang, Chien Wu-Chien, Kao Chien-Chang
Department of Surgery, Divisions of Urology, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
Department of Medical Research, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
Medicine (Baltimore). 2025 May 16;104(20):e42521. doi: 10.1097/MD.0000000000042521.
Patients with end-stage renal disease (ESRD) are predisposed to a higher risk of developing malignancies. This study aimed to explore the association between chronic dialysis with ESRD treated and the subsequent development of urothelial cell carcinoma or renal cell carcinoma (UC/RCC). Data spanning 13 years were retrieved from Taiwan's National Health Insurance Research Database. A total of 11,820 patients with ESRD undergoing maintenance dialysis between January 1, 2000, and December 31, 2013, and 35,460 controls matched for sex, age, and index year, were identified. After adjusting for confounding factors, Cox proportional hazards analysis was performed to compare the risk of UC/RCC during the 13-year follow-up period, and Kaplan-Meier analysis was used to evaluate the cumulative UC/RCC incidence between the ESRD and non-ESRD cohorts. The average time before developing UC/RCC was 4.18 years after dialysis initiation in the ESRD group compared to 5.39 years in the control group. After adjusting for sex, age, monthly income, urbanization level, geographic region, and comorbidities, the hazard ratio for UC/RCC was 1.186 (95% confidence interval, 1.071-1.448; P = .005). Stratified by age, the odds ratios (ORs) for developing UC/RCC were 2.105, 1.498, 1.371, and 0.925 among patients with ESRD aged 40 to 49, 50 to 59, 60 to 69, and ≥ 70 years, respectively. Stratification by comorbidities revealed ORs of 1.204, 1.179, 1.186,1.172, 1.211, and 1.210 for patients without diabetes mellitus, hyperlipidemia, obesity, coronary artery disease, chronic obstructive pulmonary disease, and hematuria, respectively. The mean time to UC/RCC occurrence was 4.18 years after dialysis. Furthermore, younger male patients undergoing dialysis with fewer comorbidities were at higher risk of developing UC/RCC. Early or more intensive surveillance for urological cancers post-dialysis initiation is recommended for patients undergoing dialysis with longer life expectancies or a higher likelihood of undergoing renal transplantation.
终末期肾病(ESRD)患者患恶性肿瘤的风险更高。本研究旨在探讨接受慢性透析治疗的ESRD与随后发生尿路上皮细胞癌或肾细胞癌(UC/RCC)之间的关联。从台湾国民健康保险研究数据库中检索了长达13年的数据。确定了2000年1月1日至2013年12月31日期间共11820例接受维持性透析的ESRD患者以及35460例在性别、年龄和索引年份相匹配的对照。在调整混杂因素后,进行Cox比例风险分析以比较13年随访期内UC/RCC的风险,并使用Kaplan-Meier分析评估ESRD队列和非ESRD队列之间UC/RCC的累积发病率。ESRD组在开始透析后发生UC/RCC的平均时间为4.18年,而对照组为5.39年。在调整性别、年龄、月收入、城市化水平、地理区域和合并症后,UC/RCC的风险比为1.186(95%置信区间,1.071 - 1.448;P = 0.005)。按年龄分层,40至49岁、50至59岁、60至69岁和≥70岁的ESRD患者发生UC/RCC的优势比(OR)分别为2.105、1.498、1.371和0.925。按合并症分层显示,无糖尿病、高脂血症、肥胖、冠状动脉疾病、慢性阻塞性肺疾病和血尿的患者发生UC/RCC的OR分别为1.204、1.179、1.186、1.172、1.211和1.210。发生UC/RCC的平均时间为透析后4.18年。此外,合并症较少的年轻男性透析患者发生UC/RCC的风险更高。对于预期寿命较长或接受肾移植可能性较高的透析患者,建议在开始透析后对泌尿系统癌症进行早期或更密集的监测。